16. Mathews KG, Davidson AP, Koblik PD, et al. Comparison of topical administration of clotrimazole through surgically placed
versus nonsurgically placed catheters for treatment of nasal aspergillosis in dogs: 60 cases (1990-1996). J Am Vet Med Assoc 1998;213:501-506.
17. Zonderland JL, Stork CK, Saunders JH, et al. Intranasal infusion of enilconazole for treatment of sinonasal aspergillosis
in dogs. J Am Vet Med Assoc 2002;221:1421-1425.
18. Sharp NJH, Burrell MH, Sullivan M, et al. Canine nasal aspergillosis: serology and treatment with ketoconazole. J Small Anim Pract 1984;25:149-158.
19. Sharp NJH, Harvey CE, O'Brien JA. Treatment of canine nasal aspergillosis/penicilliosis with fluconazole. J Small Anim Pract 1991;32:513-516.
20. McCarthy TC. Nasal aspergillosis in a Welsh corgi puppy. Vet Med 2002;97:731.
21. Claeys S, Lefebvre JB, Schuller S, et al. Surgical treatment of canine nasal aspergillosis by rhinotomy combined with
enilconazole infusion and oral itraconazole. J Small Anim Pract 2006;47:320-324.
22. Greci V, Stefanello D, Di Giancamillo M, et al. Sinonasal tumor in 3 dogs after successful topical treatment for frontal
sinus aspergillosis. Can Vet J 2009;50:1191-1194.
23. Schultz RM, Johnson EG, Wisner ER, et al. Clinicopathologic and diagnostic imaging characteristics of systemic aspergillosis
in 30 dogs. J Vet Intern Med 2008;22:851-859.
24. Garcia ME, Caballero J, Cruzado M, et al. The value of the determination of anti-Aspergillus IgG in the serodiagnosis of canine aspergillosis: comparison with galactomannan detection. J Vet Med B Infect Dis Vet Public Health 2001;48:743-750.
25. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003;11:272-279.
26. Kelly SE, Shaw SE, Clark WT. Long-term survival of four dogs with disseminated Aspergillus terreus infection treated with itraconazole. Aust Vet J 1995;72:311-313.
27. Morgenstern GR, Prentice AG, Prentice HG, et al. A randomized controlled trial of itraconazole versus fluconazole for
the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis
Study Group. Br J Haematol 1999;105:901-911.
28. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
N Engl J Med 2007;356:335-347.
29. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
N Engl J Med 2002;347:408-415.
30. Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared
to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46:1032-1037.
31. Rosales MS, Marsella R, Kunkle G, et al .Comparison of the clinical efficacy of oral terbinafine and ketoconazole combined
with cephalexin in the treatment of Malassezia dermatitis in dogs-a pilot study. Vet Dermatol 2005;16:171-176.
|
Featuring Information from:
